April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.1 USD | -3.57% | +2.27% | +61.35% |
05-09 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment | MT |
April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+61.35% | 5.81B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |